NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies for cancer and autoimmune diseases, today announced that William Ho, CEO and co-founder, will be presenting at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, at 9:50 am ET. William Ho will be giving a company presentation highlighting IN8bio’s latest achievements and upcoming milestones. The conference, to be held Mar ...

Core Viewpoint - IN8bio has secured a private placement financing of approximately $40.2 million to advance its γδ T cell therapies, particularly focusing on the INB-619 product candidate for cancer and autoimmune diseases [2][4]. Financing Details - The financing includes an initial closing of about $20.1 million, with the potential for an additional $20.1 million based on milestone achievements [1][4]. - The initial tranche involves the sale of 5,127,029 shares of common stock at $1.38 per share and pre-funded warrants for up to 9,452,677 shares at a price of $1.3799 [4]. - The financing is led by Coastlands Capital, with participation from other investors such as Stonepine Capital Management and 683 Capital Partners [3][4]. Use of Proceeds - The net proceeds will fund IND enabling studies for INB-619, with early animal model data expected for discussions with the FDA in 2026 and potential IND submission in 2027 [5]. - A portion of the funds will also support the submission of data from the INB-200 and INB-400 Phase 1 and Phase 2 clinical programs for glioblastoma to the FDA [5]. Company Overview - IN8bio is a clinical-stage biopharmaceutical company focused on developing γδ T cell therapies for unmet medical needs, particularly in oncology and autoimmune diseases [9][10]. - The lead program, INB-100, targets acute myeloid leukemia, while INB-200 and INB-400 focus on glioblastoma [10].

Core Insights - IN8bio, Inc. presented new preclinical data for its γδ T cell engager program, INB-619, at the 2025 ACR Convergence Meeting, highlighting its potential in treating cancer and autoimmune diseases [1][2] Preclinical Data - INB-619 demonstrated complete elimination of B cells in preclinical SLE donor models, showing efficacy comparable to FDA-approved CD19 and CD20 engagers like blinatumomab and mosunetuzumab [2][8] - The compound exhibited minimal secretion of adverse cytokines, such as IL-6, at significantly lower concentrations than currently marketed compounds [2][6] Mechanism and Safety Profile - INB-619's design allows for higher doses and deeper B cell depletion, potentially leading to an immune reset not observed with other protein engagers [3][4] - The therapy selectively expanded γδ T cells without activating CD4+ or CD8+ αβ T cells, indicating a potentially improved safety and tolerability profile [3][4] Unique Properties - INB-619 is a first-in-class, CD19-targeted, pan-γδ T cell engager that activates and expands both V-delta-1 and V-delta-2 T cell subsets, leading to effective B cell depletion [4][8] - Unlike conventional T cell engagers, INB-619 does not engage the CD3 receptor, significantly reducing the risk of toxicities such as cytokine release syndrome and neurotoxicity [5][6] Clinical Implications - The results suggest that INB-619 could transform the treatment landscape for autoimmune diseases by safely eliminating pathogenic B cells and driving immune reset [6][8] - The data indicated robust, dose-dependent B cell killing and γδ T cell expansion, maintaining a favorable cytokine profile consistent with γδ T cell biology [6][8] Company Overview - IN8bio is a clinical-stage biopharmaceutical company focused on developing γδ T cell therapies for unmet medical needs, with additional programs targeting acute myeloid leukemia and glioblastoma [7]